CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,500 enrolled
Drug / intervention
EGFR mutation testgenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01788163
NCT01788163N/ACompleted
CompareCT.gov

A Diagnostic Study to Determine the Prevalence of EGFR Mutations in Asian and Russian Patients With Advanced NSCLC of Adenocarcinoma and Non-adenocarcinoma Histologies

AstraZeneca·interventional·Posted Feb 11, 2013·Updated May 17, 2017

In Brief

A clinical study evaluating EGFR mutation test for EGFR Mutation Status in aNSCLC Patients. Completed, enrolled 3,500 participants across 71 sites in 9 countries.

Detailed Summary

Interventional diagnostic, international, multicenter and non-comparative study of EGFR mutation status in aNSCLC patients (locally advanced and/or metastatic disease) with adenocarcinoma and non-adenocarcinoma histologies. It will be conducted in Asia Pacific and Russia and will assess the current status of EGFR mutation testing, and the concordance of EGFR mutation status derived from tumour samples and blood based circulating free DNA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEGFR Mutation Status in aNSCLC Patients
CountriesAustralia, China, Indonesia, Malaysia, Russia, Singapore, South Korea, Taiwan, Thailand
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 11, 2013
Enrollment StartFeb 27, 2013
Primary CompletionAug 25, 2014
Study CompletionJun 20, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 13.4 years ago

Interventions

EGFR mutation testgenetic

EGFR mutation being tested in tissue and blood